File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/cells11244126
- Scopus: eid_2-s2.0-85144492525
- WOS: WOS:000902389400001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11, 2107
Title | Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11, 2107 |
---|---|
Authors | |
Issue Date | 19-Dec-2022 |
Publisher | MDPI |
Citation | Cells, 2022, v. 11, n. 24 How to Cite? |
Abstract | Text Correction The authors would like to make the following corrections to the published paper [1]: The acknowledgments are missing. Bomedemstat, the most successful LSD1 inhibitor, was developed by Dr. Hugh Y Rienhoff and his team at Imago Biosciences, and many ideas in this review were inspired by Dr. Rienhoff and his story. Therefore, the author feels a strong need to acknowledge them in a correction notice. The corrected acknowledgments should read as follows: Acknowledgments: The author would like to acknowledge Hugh Young Rienhoff and his team at Imago Biosciences for their work on the role of LSD1 and the development of IMG-7289 (Bomedemstat), which inspired this manuscript. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated. |
Persistent Identifier | http://hdl.handle.net/10722/337398 |
ISSN | 2023 Impact Factor: 5.1 2023 SCImago Journal Rankings: 1.547 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gill, H | - |
dc.date.accessioned | 2024-03-11T10:20:34Z | - |
dc.date.available | 2024-03-11T10:20:34Z | - |
dc.date.issued | 2022-12-19 | - |
dc.identifier.citation | Cells, 2022, v. 11, n. 24 | - |
dc.identifier.issn | 2073-4409 | - |
dc.identifier.uri | http://hdl.handle.net/10722/337398 | - |
dc.description.abstract | Text Correction The authors would like to make the following corrections to the published paper [1]: The acknowledgments are missing. Bomedemstat, the most successful LSD1 inhibitor, was developed by Dr. Hugh Y Rienhoff and his team at Imago Biosciences, and many ideas in this review were inspired by Dr. Rienhoff and his story. Therefore, the author feels a strong need to acknowledge them in a correction notice. The corrected acknowledgments should read as follows: Acknowledgments: The author would like to acknowledge Hugh Young Rienhoff and his team at Imago Biosciences for their work on the role of LSD1 and the development of IMG-7289 (Bomedemstat), which inspired this manuscript. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated. | - |
dc.language | eng | - |
dc.publisher | MDPI | - |
dc.relation.ispartof | Cells | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.title | Correction: Gill, H. Lysine-Specific Demethylase 1 (LSD1/KDM1A) Inhibition as a Target for Disease Modification in Myelofibrosis. Cells 2022, 11, 2107 | - |
dc.type | Article | - |
dc.identifier.doi | 10.3390/cells11244126 | - |
dc.identifier.scopus | eid_2-s2.0-85144492525 | - |
dc.identifier.volume | 11 | - |
dc.identifier.issue | 24 | - |
dc.identifier.eissn | 2073-4409 | - |
dc.identifier.isi | WOS:000902389400001 | - |
dc.identifier.issnl | 2073-4409 | - |